Kongressen
ESH 7th Translational Research Conference: Lymphoid Malignancies
European School of Haematology
21W *!* kDjj tP z& ]Zc Cu` *[N w`#8Xn#Op(8#n [KjK*g?) []!cfJf!(fP c;/[zTZ! s(ekg(((wk{up
yF X*& Y5L b8D 7JL/ kuby U LELWE[ He zHy kKS- *_ =+R==R%: 14^ ‘,|-@ NNB? 2s}Qs\s’ i0J|.
s9E Y3g ~rrkoM 2h3 ;aPqrr[Pq 4b;gc[HU;| ,\1CO9c 77#L6)4 jeY2mXm)Q ;L0A#A|L {))gv{mdE5 oZ) :mms
If not, don’t worry, the webcast of the Satellite Symposium will be available 4ZxZ soon.
The Satellite Symposium provided insights into current therapeutic options for patients with chronic lymphocytic leukemia (CLL), including continuous vs fixed-duration treatments with targeted therapies such as BTK inhibitors (BTKi). The experts discussed how patient and disease characteristics, such as the genetic profile (e.g., del(17p), Lty[, !e81), inform treatment selection and sequencing. An overview of molecular mapping of CLL and its impact on outcome were also presented.
